UltraGreen.ai Limited (ULG) announced on Dec, 30 2025 that it has secured regulatory approval for its Verdye indocyanine green (ICG) injectable in the Philippines and for its IC-Flow Imaging System V2 in Malaysia.

The dual clearances conclude a multi-year regulatory process and advance the company’s strategy to expand fluorescence-guided surgery across Southeast Asia, a region experiencing rapid growth in healthcare demand.

Verdye provides surgeons with a high-quality ICG dye used in multiple surgical specialties, while the IC-Flow Imaging System V2 delivers real-time fluorescence imaging to support intra-operative decision-making.

With approvals in place, UltraGreen.ai and its local partners plan to step up education, training and broader clinical adoption of ICG-based techniques among surgeons in both countries.

The company is also developing an artificial-intelligence-powered data platform aimed at enhancing surgical decision support and standardising care across various procedures.

Headquartered in Singapore, UltraGreen.ai completed its initial public offering on the Singapore Exchange in Dec, 2025, raising US$400 million at a US$1.6 billion valuation.